NASDAQ · BHST

BioHarvest Sciences Inc.

$2.03 +$0.11 (+5.73%) 1D Market open

Key Metrics

$43.52M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow −$9.58M
Beta · 1Y 1.23
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 29 high, the share price fell 61%.

    Peak close $4.94 on Jan 29; trough close $1.92 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -61%
  • Jul 21
    The stock moved -15.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 21
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 16
    The stock moved +10.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 16

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$43.52M
Enterprise value
Shares outstanding22.7M
52-wk range$1.82 – $12.80
Avg volume · 20D34.0K
Net cash
Book value / share$1.12
ExchangeNASDAQ
About BioHarvest Sciences Inc.
IPO dateFeb 11, 2019
Employees89

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio3.97
Quick ratio3.38
Debt / equity
Debt / EBITDA
Net cash
Working capital$22.82M

Cash Flow · TTM

Operating CF −$7.23M
Capex −$2.36M
Free cash flow −$9.58M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings